R A Balk - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

R A Balk

JAMA

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

JAMA|November 9, 1994

Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndromeJ G Weg, R A Balk, R S Tharratt, et al.

JAMA|February 7, 2001

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study InvestigatorsD C Angus, M C Birmingham, R A Balk, et al.

JAMA|June 15, 1994

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study GroupC J Fisher, J F Dhainaut, S M Opal, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

JAMA|November 9, 1994

Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndromeJ G Weg, R A Balk, R S Tharratt, et al.

JAMA|February 7, 2001

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study InvestigatorsD C Angus, M C Birmingham, R A Balk, et al.

JAMA|June 15, 1994

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study GroupC J Fisher, J F Dhainaut, S M Opal, et al.

Pageof 1